Co develop novel coronavirus vaccine! Step pharmaceutical subsidiary and national key laboratory to achieve cooperation!

Novel coronavirus vaccine novel coronavirus vaccine was signed jointly by Tianyuan bio and the National Key Laboratory of infectious diseases diagnosis (Zhejiang University) in February 12th There is still uncertainty about the follow-up specific implementation content and progress of the cooperation framework agreement signed this time At present, the two sides are still in the next negotiation on the cooperation terms Novel coronavirus vaccine strains are divided into 3 stages: pre clinical research, clinical research and application production approval and industrialization The work includes the separation, construction, screening and identification of new coronavirus vaccine strains, and the units involved in the Key Laboratory of Tianyuan biological and infectious diseases diagnosis (Zhejiang University) and China food and drug Testing Institute It is reported that Shandong step Pharmaceutical Co., Ltd (hereinafter referred to as "the company" or "step pharmaceutical") held the 24th (Interim) meeting of the third board of directors on January 16, 2020, deliberated and passed the proposal on capital increase of Nanjing huapai biomedical Co., Ltd and related party transactions, and the company contributed 6 yuan, The capital of Nanjing huapai biomedical Co., Ltd (hereinafter referred to as "Nanjing huapai") was increased by 1.1236 million yuan, accounting for 54.4% of the registered capital of Nanjing huapai Zhejiang Tianyuan bio Pharmaceutical Co., Ltd (hereinafter referred to as "Zhejiang Tianyuan") is a wholly-owned subsidiary of Nanjing huapai Adorable adorable